Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.83 Insider Own0.20% Shs Outstand45.27M Perf Week-13.25%
Market Cap486.20M Forward P/E- EPS next Y-3.95 Insider Trans0.00% Shs Float41.79M Perf Month-70.34%
Income-199.80M PEG- EPS next Q-1.19 Inst Own60.00% Short Float25.08% Perf Quarter-55.77%
Sales0.03M P/S18007.40 EPS this Y-2.40% Inst Trans-3.56% Short Ratio5.44 Perf Half Y-66.91%
Book/sh2.96 P/B3.63 EPS next Y18.90% ROA-83.80% Target Price35.25 Perf Year-13.32%
Cash/sh2.21 P/C4.87 EPS next 5Y-0.20% ROE-108.40% 52W Range11.10 - 41.97 Perf YTD-72.16%
Dividend- P/FCF- EPS past 5Y-15.90% ROI-53.10% 52W High-74.41% Beta1.36
Dividend %- Quick Ratio3.20 Sales past 5Y-11.10% Gross Margin- 52W Low-3.24% ATR1.89
Employees204 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)15.12 Volatility8.49% 10.23%
OptionableYes Debt/Eq0.19 EPS Q/Q-76.10% Profit Margin- Rel Volume1.16 Prev Close12.22
ShortableYes LT Debt/Eq0.14 EarningsFeb 25 BMO Payout- Avg Volume1.93M Price10.74
Recom2.10 SMA20-39.23% SMA50-63.41% SMA200-63.15% Volume2,231,413 Change-12.11%
Jan-19-16Downgrade RBC Capital Mkts Outperform → Sector Perform $62 → $15
Jan-15-16Downgrade Piper Jaffray Overweight → Neutral
Oct-23-15Resumed BofA/Merrill Buy
Oct-23-15Initiated Jefferies Hold $28
Oct-02-15Reiterated Needham Buy $38 → $55
Aug-26-15Reiterated ROTH Capital Buy $50 → $45
Aug-26-15Reiterated ROTH Capital Buy $45 → $50
Aug-24-15Upgrade Piper Jaffray Neutral → Overweight $28 → $48
Aug-07-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
May-22-15Reiterated WBB Securities Strong Buy $25 → $35
May-21-15Downgrade BofA/Merrill Buy → Neutral
May-20-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy $14 → $33
May-20-15Upgrade Canaccord Genuity Hold → Buy $16 → $30
May-20-15Reiterated Wedbush Neutral $16 → $25
May-20-15Reiterated ROTH Capital Buy $22 → $45
May-20-15Reiterated RBC Capital Mkts Sector Perform $15 → $20
May-06-15Upgrade Robert W. Baird Neutral → Outperform $16 → $20
Mar-02-15Reiterated Needham Buy $52 → $38
Jan-23-15Initiated RBC Capital Mkts Sector Perform $15
Nov-26-14Upgrade WBB Securities Buy → Strong Buy $25 → $25
Feb-08-16 04:28PM  Why Sarepta Therapeutics Inc. Is Down Today at Motley Fool -12.11%
01:01PM  Sarepta Therapeutics Dropped 10% Following FDA News
11:38AM  Sarepta's Duchenne drug decision delayed: Why it could help win approval at
10:33AM  [$$] FDA Extends Sarepta's Muscular Dystrophy Drug Deadline at The Wall Street Journal
08:45AM  Sarepta says FDA delays decision on muscle-wasting disorder drug Reuters
08:30AM  Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen Business Wire
Feb-07-16 02:40PM  Why Shares of Sarepta Therapeutics Inc. Collapsed in January at Motley Fool
Feb-05-16 11:40AM  Will Sarepta reverse after steep drop?
Feb-04-16 02:29PM  Its Time to Buy This Biotech Gem
Feb-02-16 05:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-01-16 11:30AM  Top 10 BioFlash stories in January: Duchenne news dominates once again at
06:08AM  Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date? at TheStreet
Jan-31-16 10:20AM  3 Key FDA Decisions Expected in February at 24/7 Wall St.
Jan-27-16 02:01PM  Structural Volatility Won't End For Several Years, Derivatives Strategist Says
Jan-26-16 05:30PM  Bragar Eagel & Squire, P.C. Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
06:45AM  Akashi suspends drug trial in latest setback for Duchenne community at
12:06AM  Changes in BioMarins Valuation Multiples
Jan-25-16 10:41AM  3 Ways to Lose All Your Money in the Stock Market at Motley Fool
08:10AM  Duchenne drug by Cambridge's Catabasis looks safe in early trial at
Jan-24-16 09:29PM  IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Sarepta Therapeutics, Inc. and Advises Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
11:00AM  Biotech Stock Mailbag: Snow Stops Sarepta's FDA Show, so What's Next? at TheStreet
Jan-22-16 07:47PM  Lifshitz & Miller Law Firm Announces Investigation of GoPro Inc., Iconix Brand Group, Inland Real Estate Corporation, Nobilis Health Corp., Sarepta Therapeutics, Inc., Synutra International Inc., and Wilshire Bancorp Inc. PR Newswire
03:38PM  Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
02:41PM  Snowstorm Dashes Hopes for Sarepta Drug's Dystrophy Patients at Bloomberg
02:23PM  Is There Hope For Sarepta Therapeutics? Yes, A Bit at Forbes
Jan-21-16 11:23AM  The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug -9.73%
08:11AM  FDA Snow Delay Adds To Woes For Sarepta's Muscular Dystrophy Med at Forbes
08:00AM  Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta Accesswire
Jan-20-16 10:09PM  INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Sarepta Therapeutics, Inc. and Strongly Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:20PM  Snow delays FDA hearing; Duchenne drug advocates vow to redouble efforts at
08:01PM  Muscular Dystrophy Drugs Face New FDA Questions at The Wall Street Journal
07:42PM  FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area Business Wire
04:32PM  Keep An Eye On Sarepta Heading Into Friday's FDA Panel On Eteplirsen
03:50PM  Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie
02:40PM  Four big problems with the FDAs analysis of Sareptas Duchenne drug data at
Jan-19-16 12:20PM  Science, and not patients, will turn the tide for Sarepta's Duchenne drug at -5.88%
11:29AM  8 Things That Could Lift Biotech Stocks Out of Bear Market at TheStreet
09:00AM  Wolf Popper LLP Announces Investigation of Fraud Claims on Behalf of Investors in Sarepta Therapeutics, Inc. PR Newswire
07:01AM  Trending Now: SRPT
06:21AM  Sarepta Therapeutics downgraded by RBC Capital Mkts
Jan-18-16 02:35PM  Sarepta Tanks, Eteplirsen Briefing Document Raises Concerns
Jan-16-16 09:01PM  IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against Sarepta Therapeutics, Inc. and Strongly Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:25AM  5 Stocks That Punished Shareholders Last Week at 24/7 Wall St.
Jan-15-16 10:42PM  [$$] FDA Delivers Latest Biotech Blow at The Wall Street Journal -54.85%
06:41PM  Why Intel, Sarepta Therapeutics, and Sprint Slumped Today at Motley Fool
04:41PM  Intel, Hyatt and Chevron fall and Wynn Resorts rises
03:46PM  SHAREHOLDER ALERT: Abraham, Fruchter & Twersky, LLP Announces An Investigation of Sarepta Therapeutics, Inc. (SRPT) Business Wire
03:13PM  [$$] Setback for Sarepta Drug, But Approval Still Possible at
02:34PM  Sarepta plunges on negative FDA drug review
02:19PM  How to Trade 3 of the Market's Most Active Stocks at TheStreet
01:57PM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launch Investigation of Sarepta Therapeutics, Inc. for Possible Breaches of Fiduciary Duty Business Wire
12:53PM  Sarepta Plummets As FDA Slams Muscular Dystrophy Drug at Investor's Business Daily
12:50PM  Duchenne mom: FDA is looking for reasons to deny Sareptas drug at
12:25PM  Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting at TheStreet
12:14PM  Sarepta: 'Approval Unlikely,' Shares Tank at
12:07PM  Sarapeta (SRPT) Stock Plummets on FDA Report at TheStreet
11:47AM  Is Peter Schiff's Recession Thesis Coming True?
11:32AM  Sarepta Therapeutics shares tank as hopes for new drug approval fade at MarketWatch
11:01AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Sarepta Therapeutics, Inc. - SRPT PR Newswire
10:20AM  Here's Why Sarepta Therapeutics Is Getting Crushed Today at Motley Fool
10:16AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sarepta Therapeutics Inc. (SRPT) PR Newswire
10:11AM  FDA Delivers Latest Biotech Blow at The Wall Street Journal
10:05AM  Why Sarepta Therapeutics Is Cratering at 24/7 Wall St.
10:04AM  Four of the Biggest Movers on a Volatile Friday Morning at Insider Monkey
09:16AM  Sarepta Crashes 50% Amid Efficacy Concern Related To Eteplirsen
08:24AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
07:15AM  Packed house expected at the FDAs Duchenne drug hearing next week at
05:00AM  BioMarin's FDA Defeat Has Pharma Investors Looking for Lessons at Bloomberg
12:22AM  [$$] FDA Rejects New Drug Application for BioMarins Duchenne Treatment at The Wall Street Journal
Jan-14-16 05:52PM  Biotech name to watch
03:07PM  Now that outbreak is over, whatever happened to Ebola stocks? at MarketWatch
01:12PM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : January 14, 2016
12:29PM  BioMarin Muscular Dystrophy Drug Rejected By FDA at Investor's Business Daily
12:03PM  [$$] FDA Rejects New Drug Application for BioMarin's Duchenne Treatment at The Wall Street Journal
11:36AM  FDA rejects BioMarin's muscle wasting drug; Sarepta drug in focus Reuters
08:06AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : January 14, 2016
Jan-13-16 03:04PM  The FDA's Change of Heart Sends Sarepta Therapeutics' Shares Soaring in 2015 at Motley Fool -5.80%
01:41PM  3 Biotechs With Major Catalysts Incoming at Motley Fool
11:40AM  Duchenne pioneer says FDA rejection of Sareptas drug would be a travesty at
Jan-12-16 08:02AM  These Biotech Stocks Could Double in 2016 at Motley Fool
Jan-11-16 02:01PM  Yes, this company has rare disease news, but there's much more to come at
Jan-08-16 11:58AM  Patient-funded biotech in $100 mln funding deal for DMD drug Reuters
08:07AM  Big health-care confab: Where are the bulls? at CNBC
Jan-07-16 12:17PM  5 Biotech Stocks That Doubled in 2015
Jan-06-16 07:20AM  This hedge fund won biotech space...
Jan-04-16 04:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-31-15 05:21PM  3 biotech catalysts in 2016
Dec-30-15 04:25PM  Sarepta's DMD Drug Eteplirsen to Face FDA Panel in January
Dec-29-15 11:55AM  Here are the Mass. biotechs that saw the biggest stock gains in 2015 and why at
Dec-23-15 12:56PM  Why Celgene May be the Best Biotech in the World
Dec-22-15 08:10PM  Niche Hedge Funds lead the pack in 2015
Dec-18-15 08:43AM  BioMarin says FDA to delay deciding on approval of DMD drug Reuters
07:04AM  Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Business Wire
Dec-14-15 02:53PM  Here are the 20 top-performing stocks in Mass. for 2015 at
Dec-08-15 01:17PM  SAREPTA THERAPEUTICS, INC. Financials
Dec-06-15 11:00AM  3 Stocks We're Ready to Sell at Motley Fool
Dec-05-15 08:03AM  Why a Failure By BioMarin Caused Sarepta's Shares to Spike 53% in November at Motley Fool
Dec-04-15 10:59AM  Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy? at Insider Monkey
Dec-03-15 12:18PM  These Biotech Stocks Could Face a Cash Crunch in 2016 at Motley Fool
Dec-02-15 10:20AM  4 Top Jefferies Biotech and Specialty Pharma Growth Stocks to Buy Now at 24/7 Wall St.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDSVP & Chief Medical OfficerFeb 27Buy11.828009,4521,311Mar 03 06:48 PM
Christopher Nishan GarabedianPresident and CEOFeb 27Buy11.828009,45229,552Mar 03 06:47 PM